ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen To Buy KAI Pharma For $315 Million In Cash

DOW JONES NEWSWIRES Amgen Inc. (AMGN) has agreed to acquire privately held company KAI Pharmaceuticals for $315 million in cash, giving the drug maker rights to an experimental drug to treat chronic kidney disease. In connection with the deal, Amgen is providing a loan prior to closing for Phase 3 clinical testing of KAI-4169, a drug that is being studied for the treatment of secondary hyperparathyroidism, a common complication for patients who are on dialysis. The deal will give Amgen rights to KAI-4169, outside of Japan. "KAI has demonstrated encouraging results in the clinic. We are excited about acquiring KAI, as well as the opportunity to potentially deliver a novel therapy for chronic kidney disease patients on dialysis suffering from secondary hyperparathyroidism," said Sean E. Harper, executive vice president of research and development at Amgen. Amgen, the biggest stand-alone biotechnology company, has been making acquisitions in a bid to bolster its research-and-development pipeline as sales growth for older drugs has slowed. The transaction, which has been approved by KAI stockholders and both companies' boards, is subject to regulatory approvals. After the deal is completed, KAI will become a wholly owned unit of Amgen. Amgen shares closed at $67.02 on Monday and were inactive in premarket trading. The stock is up 4.4% so far this year. ---By Kristin Jones, Dow Jones Newswires; 212-416-2208; kristin.jones@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
07/30/201414:45:16MARKET SNAPSHOT: S&P 500 Turns Positive As Fed Calms Rate-hike...
07/30/201413:15:33MARKET SNAPSHOT: U.S. Stocks Fall On Rate-hike Fears
07/30/201410:56:51MARKET SNAPSHOT: U.S. Stocks Pare Gains On Rate-hike Fears
07/30/201409:51:21MARKET SNAPSHOT: U.S. Stocks Open Higher After Strong GDP Report
07/30/201409:45:11U.S. Hot Stocks: Hot Stocks to Watch
07/30/201409:12:33MARKET SNAPSHOT: U.S. Stocks: Futures Add To Gains After GDP;...
07/30/201408:16:19MARKET SNAPSHOT: U.S. Markets: Futures Up With Twitter, GDP...
07/25/201406:03:01Bayer and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment...
07/02/201417:06:33Bind Therapeutics, Amgen End Collaboration on Targeted Cancer...
06/20/201421:35:07Atara Biotherapeutics, Backed by Carlos Slim, Files for IPO
06/09/201418:12:243M Finance Chief Departs for Amgen -- 2nd Update
06/09/201417:08:393M Finance Chief Departs for Amgen -- Update
05/12/201402:54:55AstraZeneca, Amgen Announce Positive Phase III Brodalumab Study
05/09/201418:31:12Amgen, AstraZeneca Announce Positive Results from Brodalumab...
04/22/201419:35:35Correction to Amgen Earnings Story
04/20/201406:17:33MARKET SNAPSHOT: Long View On Stocks Is Best During Weak Earnings...
04/11/201419:36:07Riding the Tech Roller Coaster
03/30/201408:44:49New Drugs to Lower Cholesterol Show Promise: Studies
03/26/201416:30:44Merck, Glaxo Hold Off on Help With Affordable Care Act Copays
03/17/201410:14:16Amgen Says Cholesterol Drug Study Meets Primary Endpoint

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad